Engineering

Overview

Part 1 pCDFDuet1-TktA-AroF-AroE (BBa_259TIJNK)

Design:
Build:

Part 2 pETDuet1-TyrA(K12)-HpaB-HpaC (BBa_25TX8LQL)

Design:
Build:

Part 3 pETDuet1-TyrA(SO)-HpaB-HpaC (BBa_256I72YK)

Design:
Build:

Part 4 pETDuet1-TyrA(HI)-HpaB-HpaC (BBa_25L16LN5)

Design:
Build:

Test1:

1. Target protein expression test
2. Detection of L-dopa production using an ELISA test kit

Learn1:

Part 5 pETDuet1-TyrA(K12)-RBS2-HpaB-HpaC (BBa_256PUDZB)

Design:
Build:

Part 6 pETDuet1-TyrA(K12)-RBS3-HpaB-HpaC (BBa_25ZKRZOR)

Design:
Build:

Test2:

1. Detection of L-dopa production using an ELISA test kit
2. Functional test

Learn2:

References

Overview

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease[1]. It is most common in people aged 65 and older and is closely associated with aging[2]. With the accelerating aging of the global population, the number of PD patients is increasing dramatically, resulting in a significant economic and medical burden. The primary pathological features of PD are abnormal aggregation of α-synuclein (α-syn) and loss of dopaminergic neurons in the substantia nigra of the midbrain[3]. It is characterized by motor and non-motor symptoms, which severely impact patients' quality of life. Studies have found that most PD patients experience gastrointestinal symptoms, such as nausea, constipation, and delayed gastric emptying[4]. Approximately 80% of PD patients experience constipation, and constipation symptoms typically develop 10 years or more earlier than motor symptoms[5-6]. In recent years, increasing research has demonstrated a close association between the gut microbiome and PD. Therefore, clarifying the mechanisms of action of the gut microbiome in PD may provide new insights into PD intervention and treatment. The research and application of levodopa also holds significant significance in the field of neuroscience. Combining beneficial probiotic strains with levodopa could provide insights into the development of new treatments and medications[7-8].

Part 1 pCDFDuet1-TktA-AroF-AroE (BBa_259TIJNK)
Design:

The pCDFDuet1 plasmid was provided by the strain library of our unit, and the target genes TktA、AroF and AroE were all fragments amplified from the genome using primers using Escherichia coli K12 as templates. The three target genes were constructed together with the vector using the homologous recombination method.

Figure 1. The plasmid map of pCDFDuet1-TktA-AroF-AroE

Build:

We used homologous recombination to construct the pCDFDuet-tktA-aroF-aroE plasmid. First, using PCR technology, we designed corresponding primers and amplified the target fragments of tktA, aroF, and aroE using Escherichia coli K12 as a template. We also amplified the pCDFDuet plasmid backbone using a laboratory-preserved plasmid. As we can see from Figure 2A, the agarose gel electrophoresis results after amplification showed that the amplified lengths of the backbone and target fragments were all in line with the expected sizes. The pCDFDuet plasmid backbone is 3781 bp in length, tktA is 1995 bp in length, aroF is 1071 bp in length, and aroE is 819 bp in length.

After obtaining the empty vector and fragments of corresponding lengths, we recovered the agarose gel to obtain the purified vector and fragments, and obtained the concentration of these gene fragments through the nanodrop instrument. After obtaining the corresponding concentration, we used homologous recombination to allow the vector and fragments to be recombined together. Then we transformed the recombinant product into the E. coli cloning strain TOP10. As shown in Figure 2B, after the transformation and overnight growth, we saw that there were single colonies with successful transformation. However, whether the transformation was successful or not, we need to perform corresponding verification.

First, by colony PCR, we randomly selected 4 independent single colonies of the same size on the plate and used colony PCR primers for identification. The length was designed to be 2102bp. In PCR After amplification and identification by agarose gel electrophoresis, we found that the size of the amplified fragments met our expectations. Therefore, these single clones were considered to have successfully transformed with the recombinant plasmid.

Finally, we need to expand and culture the corresponding correct single clones, extract the plasmids, and send them to a biological company for sequencing. The purpose of this step is to ensure the position and order of our vector and connector, and whether there are any base deletions or mutations. Figure 2D shows that our construction results are correct. At this point, our first recombinant plasmid was successfully constructed.

Figure 2. A. Electrophoresis results of plasmid backbone and target fragment, B. Recombinant plasmid transformed into cloning strain TOP10, C. Electrophoresis results after single clone colony PCR, D. Plasmid sequencing results

Part 2 pETDuet1-TyrA(K12)-HpaB-HpaC (BBa_25TX8LQL)
Design:

The pETDuet1 plasmid was provided by the strain library of our unit, and the target genes TyrA(K12), HpaB and HpaC were all fragments amplified from the genome using primers using Escherichia coli K12 as templates. The three target genes were constructed together with the vector using the homologous recombination method.

Figure 3. The plasmid map of pETDuet1-TyrA(K12)-HpaB-HpaC

Build:

We used E. coli K12 as a template to amplify other target fragments. First, we designed corresponding primers and then used cultured E. coli K12 as a template to amplify the target genes TyrA, hpaB, and hpaC. The plasmid backbone was also obtained by inverse PCR. After the amplification reaction, the amplified products were identified by agarose gel electrophoresis. The results showed that the plasmid backbone and the three target genes were successfully amplified. The backbone length was 5420 bp, the length of TyrA was 1122 bp, the length of hpaB was 1563 bp, and the length of hpaC was 513 bp, as can be seen in Figure 4.

Figure 4. Electrophoresis results of pETDuet and TyrA(K12), hpaB and hpaC

After obtaining the gene fragment of the correct size, we need to recover the purified vector and fragment by gel recovery. Then, we use homologous recombination to construct the complete recombinant plasmid. Next, we need to transform it into a cloning strain and, after overnight growth, select the grown single clones for colony PCR identification. As shown in Figure 5, we selected six single clones and amplified them using the designed primers. The results showed that the amplified length was 1500bp, which is consistent with the expected length, indicating that the transformation process was successful.

Figure 5. Results of monoclonal plates and colony PCR after transformation

Finally, we inoculated the successful transformants into seed solution, cultured them, extracted the plasmids, and sent them to a biotechnology company for sequencing. The results are shown in Figure 6. The sequencing results show that the constructed recombinant plasmids have no base mutations or deletions.

Figure 6. Plasmid sequencing results

Part 3 pETDuet1-TyrA(SO)-HpaB-HpaC (BBa_256I72YK)
Design:

The pETDuet1 plasmid was provided by the strain library of our unit, and the target genes TyrA(SO) is synthesized by a biological company, HpaB and HpaC were all fragments amplified from the genome using primers using Escherichia coli K12 as templates. The three target genes were constructed together with the vector using the homologous recombination method.

Figure 7. The plasmid map of pETDuet1-TyrA(SO)-HpaB-HpaC

Build:

we constructed the pETDuet-TyrA(SO)-hpaB-hpaC plasmid. Compared with pETDuet-TyrA(K12)-hpaB-hpaC, the difference between the two plasmids is the source of TyrA. Therefore, we used homologous recombination to replace TyrA based on pETDuet-TyrA(K12)-hpaB-hpaC. We designed two pairs of primers, one to amplify the TyrA gene from the new source, and the other pair of primers to amplify the rest of the pETDuet-TyrA(K12)-hpaB-hpaC except TyrA(K12). After amplification, agarose gel electrophoresis was performed for identification, as shown in Figure 8A. As shown in Figure 8B , the plasmid backbone and TyrA(SO) amplification results after electrophoresis were consistent with the expected lengths: the plasmid backbone was 7535 bp long, and TyrA(SO) was 1152 bp long. The two fragments were then recovered and purified from the gel. After homologous recombination, the recombinant products were transformed into E. coli TOP10. As shown in Figure 8B , single clones emerged after overnight growth. To verify the correctness of the transformed single clones, we performed colony PCR identification. Twelve single clones were selected for identification. In Figure 8C , the colony PCR result showed a size of 2100 bp, demonstrating that the transformed single clones all contained the correct plasmid. The correct single clones were then inoculated into seed solution, and the plasmids were extracted and sent to a biotechnology company for sequencing. Sequencing results confirmed that the constructed plasmid was successful.

Figure 8 A. Electrophoresis results of plasmid backbone and target gene fragments, B. Plate of recombinant plasmid transformed into E. coli, C. Electrophoresis results of monoclonal colony after PCR, D. Sequencing results of recombinant plasmid

Part 4 pETDuet1-TyrA(HI)-HpaB-HpaC (BBa_25L16LN5)
Design:

The pETDuet1 plasmid was provided by the strain library of our unit, and the target genes TyrA(HI) is synthesized by a biological company, HpaB and HpaC were all fragments amplified from the genome using primers using Escherichia coli K12 as templates. The three target genes were constructed together with the vector using the homologous recombination method.

Figure 9. The plasmid map of pETDuet1-TyrA(HI)-HpaB-HpaC

Build:

When constructing pETDuet-TyrA(HI)-hpaB-hpaC, we used a similar approach to pETDuet-TyrA(SO)-hpaB-hpaC. We first designed primers to amplify the TyrA(HI) target gene, and another pair of primers to amplify the backbone. After amplification, we verified the success of the amplification by agarose gel electrophoresis. As shown in Figure 10A, the amplified vector and target gene lengths were consistent with the expected values, with the backbone being 7535 bp and the target gene being 1146 bp. Following amplification, the two were ligated by homologous recombination and transformed into the corresponding E. coli cloning strain. After overnight growth, as shown in Figure 10B, 12 single colonies were selected for colony PCR analysis to confirm the success of the transformants.

Figure 10 A. Plasmid backbone and target gene electrophoresis results. B.plate image of the transformed single colonies.

After selecting the corresponding single clone for colony PCR, we performed electrophoresis analysis on the amplified product. Figure 11A shows that the colony PCR result met the expected length of 2000 bp. Furthermore, we selected a single clone that successfully obtained colony PCR and inoculated it into seed solution. The plasmid was then extracted and sent to a biotechnology company for sequencing. The results are shown in Figure 11B. The sequencing results indicate that the recombinant plasmid construction was successful, with no base mutations or deletions.

Figure 11 A. Plasmid backbone and target gene electrophoresis results. B.plate image of the transformed single colonies.

Test1:
1. Target protein expression test

After constructing Plasmid 1 (pCDFDuet1-TktA-AroF-AroE) and the three TyrA plasmids 2, we need to transform two plasmids into a new E. coli expression strain. Because the production of L-DOPA requires the simultaneous function of all six genes, we first transform two plasmids into E. coli BL21 (DE3), as shown in Figure 12. After overnight growth, we see that the double-transformed host bacteria have corresponding monoclonal colonies growing. We will then perform colony PCR to verify whether the double plasmid transformation is successful.

Figure 12. The corresponding single colony plate image after plasmid 1 and plasmid 2 were transformed into BL21 (DE3) together

After the double plasmid transformation is completed, we need to perform colony PCR identification. Since there are two plasmids, two pairs of primers need to be designed to identify each plasmid separately. Therefore, colony PCR is performed on each single clone of strain1-3. The corresponding lengths are: plasmid 1 of strain1 is 1000bp, plasmid 2 is 800bp, plasmid 1 of strain2 is 800bp, plasmid 2 is 1000bp, and plasmid 1 of strain3 is 1000bp, plasmid 2 is 1000bp. After the amplification is completed, we perform agarose gel electrophoresis. The results are shown in Figure 13. The lengths of all colony PCRs are in line with the expected size. Therefore, the double plasmid transformation is considered successful.

Figure 13. Electrophoresis of colony PCR results of three strains after double plasmid transformation

Before conducting the first round of fermentation tests, we needed to perform protein expression tests on the two plasmids to initially verify the normal expression of our six genes in E. coli. Therefore, we transformed BL21 (DE3) host cells with plasmid 1 (pCDFDuet-tktA-aroF-aroE) and plasmid 2 (pETDuet-TyrA(K12)-hpaB-hpaC) for protein expression. This round of protein expression testing employed rapid induction, using a temperature of 37°C, a rotational speed of 220 rpm, an inducer concentration of 1 mM IPTG, and a duration of 6 hours.

After induction, we collected the protein and divided it into the supernatant and precipitate of crude protein for SDS-PAGE identification to observe whether the expression of the target gene was successful. As shown in Figure 14, wells 1-4 are the supernatant of plasmid 1, 5 is the precipitate of plasmid 1, wells 6-8 are the supernatant of plasmid 2, and 9-10 are the precipitate of plasmid 2. Plasmid 2 contains inclusion bodies, and the proteins corresponding to the target genes are all successfully expressed. Although the target protein corresponding to plasmid 2 has inclusion bodies during the collection process, this may be related to the operational steps in the protein collection process. In addition, since we are strengthening the L-dopa biosynthesis pathway in the cell, we confirm that the expression has achieved our goal.

Figure 14. Target protein expression test using plasmids 1 (pCDFDuet-tktA-aroF-aroE) and 2 (pETDuet-TyrA(K12)-hpaB-hpaC). Wells 1-4 contain the supernatant from plasmid 1, and well 5 contains the precipitate from plasmid 1. Wells 6-8 contain the supernatant from plasmid 2, and wells 9-10 contain the precipitate from plasmid 2.

2. Detection of L-dopa production using an ELISA test kit

After confirming that our target proteins are expressed normally, we need to perform fermentation tests on the previously constructed strains carrying TyrA from three sources in order to obtain the optimal TyrA. The fermentation method is consistent with the protein expression conditions, and the fermentation time is 48 hours. Three replicates are set for each strain fermentation, as shown in Figure 15A. After the fermentation is completed, we use the L-DOPA Elisa detection kit for measurement. The sample preparation, reaction process, and reaction termination are shown in Figures 15BCD. Finally, we use a microplate reader to measure the absorbance value at 450nm Figures 15E.

Figure 15. A. Fermentation test of strain 123 (three replicates), B. Sample preparation, C. Reaction, D. End of reaction, E. Absorbance test

We first developed a standard curve, as shown in Figure 16A. We then calculated the L-DOPA content in the sample based on the standard curve and absorbance values. It can be seen that strain 1 had the highest L-DOPA production, as shown in Figure 16B. That is, TyrA derived from K12 showed better enzyme activity in the modified strain. For this modified strain, genes derived from similar species have better adaptability, so this gene was selected for subsequent RBS screening.

Figure 16. A. Standard curve of the ELISA test kit; B. L-DOPA production by three strains, where Strain 1 contains TyrA from K12, Strain 2 contains TyrA from SO, and Strain 3 contains TyrA from HI.

Learn1:

Our overall technical approach involves first constructing a complete L-DOPA production route. The construction of the L-DOPA production pathway in E. coli is divided into two modules. Module 1, Plasmid 1, serves as an enhanced precursor supply, strengthening the rate-limiting enzymes in the PPP and glycolysis pathways and enhancing the metabolic flux of PEP and E4P to the shikimate pathway. Module 2, Plasmid 2, enhances the key precursors in the shikimate pathway that lead to L-DOPA production and the key enzymes for L-DOPA synthesis. Product production is achieved by enhancing pathway carbon flux and product synthesis, respectively.After finalizing the route, the second step involves comparing the effects of TyrA genes from three different sources. This step aims to identify the optimal TyrA gene, as it determines the critical rate-limiting step in L-DOPA synthesis. Fermentation testing will identify the optimal TyrA gene source and use this plasmid for subsequent transformations.

The final results showed that TyrA from the same species exhibited better enzymatic activity in the modified strain. For this modified strain, genes from similar species have better adaptability, but we still hope to improve this rate-limiting step, so this gene was selected for subsequent RBS screening.

Part 5 pETDuet1-TyrA(K12)-RBS2-HpaB-HpaC (BBa_256PUDZB)
Design:

The construction of pETDuet1-TyrA(K12)-RBS2-HpaB-HpaC is based on pETDuet1-TyrA(K12)-HpaB-HpaC. It only needs to design the new RBS sequence on the primer and amplify it with the original plasmid as the template. The completed plasmid is pETDuet1-TyrA(K12)-RBS2-HpaB-HpaC with the RBS sequence replaced. We then sequenced the plasmid to ensure that there was no deletion or mutation at the replaced position.

Figure 17. The plasmid map of pETDuet1-TyrA(K12)-RBS2-HpaB-HpaC

Build:

To replace the RBS at the start of the TyrA gene in the pETDuet-TyrA(K12)-hpaB-hpaC plasmid, we used inverse PCR. We designed a pair of primers targeting the desired RBS sequence and amplified the plasmid using the original pETDuet-TyrA(K12)-hpaB-hpaC plasmid as a template. Compared to the original plasmid, only the RBS sequence was altered in the amplified plasmid. Because the newly amplified plasmid was essentially the same length as the original, we avoided agarose gel electrophoresis and instead performed transformation after amplification and extracted the plasmid for sequencing.The sequencing results in Figure 19 demonstrate the successful replacement of the new RBS sequence. The sequence on the left represents the replacement of RBS2.

Part 6 pETDuet1-TyrA(K12)-RBS3-HpaB-HpaC (BBa_25ZKRZOR)
Design:

The construction of pETDuet1-TyrA(K12)-RBS3-HpaB-HpaC is based on pETDuet1-TyrA(K12)-HpaB-HpaC. It only needs to design the new RBS sequence on the primer and amplify it with the original plasmid as the template. The completed plasmid is pETDuet1-TyrA(K12)-RBS2-HpaB-HpaC with the RBS sequence replaced. We then sequenced the plasmid to ensure that there was no deletion or mutation at the replaced position.

Figure 18. The plasmid map of pETDuet1-TyrA(K12)-RBS3-HpaB-HpaC

Build:

The construction of this step is consistent with the method of replacing RBS2,The sequencing results in Figure 19 demonstrate the successful replacement of the new RBS sequence. The sequence on the right represents the replacement of RBS3.

Figure 19. Sequencing results after replacing the RBS sequence

Test2:
1. Detection of L-dopa production using an ELISA test kit

After the RBS sequence replacement was completed, fermentation testing was repeated to determine which RBS sequence performed best. Three strains were inoculated into LBG (20 g/L glucose) medium at an initial OD of 0.05. After fermentation, product testing was performed to identify the optimal RBS sequence for the TyrA gene and improve expression of the key enzyme.

The fermentation testing steps were similar to those described above. Three replicates of different RBS strains were tested, as shown in Figure 20A. The assays were performed using a kit, with the reaction progressing and reaction completion times (Figure 20BC). Finally, the fermentation yields were calculated using a standard curve.

Figure 20. A Fermentation test of different RBS strains (three replicates), BC is divided into reaction progress and reaction completion

By substituting the absorbance value into the standard curve for calculation, we can obtain the amount of L-dopa produced by the strain under different RBS sequences. According to the bar graph in Figure 21, the three different RBS sequences do have a certain effect on gene expression. Among the RBS sequences we screened, the optimal expression level increased the strain's yield by 16.4%, reaching 500.3 mg/L.

Figure 21. The yield of levodopa corresponding to different RBS sequences

2. Functional test

At this point, we have confirmed the optimal TyrA source (K12) and RBS sequence TCACACAGG. We then initially tested the effect of different glucose concentrations on L-DOPA production by fermentation in the BL21 (DE3) host strain. We set initial glucose concentrations of 10 g/L, 20 g/L, 30 g/L, 40 g/L, and 50 g/L, and the fermentation conditions were the same as before, After this, we will add some new parameters to explore the factors affecting levodopa production, such as inducer concentration and time.

Figure 22 shows that the yield of the strain increased with increasing glucose concentration, reaching a peak of 689.3 mg/L. However, as the glucose concentration continued to increase to 50 g/L, the yield began to decline. We speculate that the high glucose concentration affected the strain's metabolism, resulting in a decrease in yield.

Figure 22. Analysis of results at different initial sugar concentrations (optimal RBS sequence strain)

To further explore the factors affecting levodopa, we simultaneously investigated the inducer concentration, glucose concentration, and fermentation time. The glucose concentration was still set at 10 g/L to 50 g/L, with 5 gradients, and the inducer concentration was 0, 0.2, 0.4, 0.6, 0.8, 1.0 mM, with 6 gradients, and the fermentation time was 36 h and 48 h. The strain was inoculated into LBG medium with an initial OD of 0.05. After the fermentation was completed, the product was tested.

63080ce321ff2d29e92777e1eaebd1a4

Figure 23. Effects of inducer concentration and glucose concentration on levodopa production at different times

The results showed significant differences in L-DOPA yields across different conditions, with overall yield levels increasing over time. Results at 36 hours (Figure 23A) show that L-DOPA yields were concentrated in the 50–100 pg range across most conditions. Yields generally increased with increasing IPTG concentrations, but there was significant variability among glucose levels. At 0 mM IPTG, yields were generally low across all glucose conditions, ranging from 20–40 pg. At 0.2–0.4 mM IPTG, yields reached the highest levels at 20 g/L and 30 g/L glucose, reaching 90–100 pg, while yields at 0 g/L and 10 g/L were lower. At 0.8–1.0 mM IPTG, 40 g/L glucose performed exceptionally well, exceeding 100 pg, while other conditions generally fell below this level. In summary, at 36 hours, at moderate IPTG levels (0.4–0.6 mM), 20–30 g/L glucose was more favorable, while at high IPTG levels (0.8–1.0 mM), 40 g/L glucose performed best.

The 48-hour results (Figure 23B) showed that overall yield levels at 48 hours increased further compared to 36 hours, exceeding 120 pg in some conditions. Under 0 mM IPTG, the 40 g/L glucose group achieved the highest yield, approximately 75–80 pg, while the other groups ranged from 45–55 pg. Extreme differences were observed at 0.2 mM IPTG: Yields at 20–40 g/L glucose levels were high, reaching 80–100 pg, but at 10 g/L, yields were nearly zero, the lowest of all conditions. At 0.4–0.6 mM IPTG, the yields at 30 g/L and 40 g/L glucose levels remained high (approximately 90–110 pg), significantly higher than those at 0–10 g/L. At 0.8–1.0 mM IPTG, the 40 g/L glucose group reached its highest peak, reaching 120–130 pg, while the 0 g/L and 10 g/L conditions were significantly lower, only around 50–70 pg.

Results Summary

1. A significant time effect: The overall yield at 48 hours was higher than at 36 hours, with the maximum increase being even more significant.

2. The optimal condition was prominent: The yield reached its highest level (approximately 120–130 pg) at high IPTG concentrations (0.8–1.0 mM) combined with high glucose concentrations (40 g/L), reaching the peak among all conditions.

3. Large variability at low IPTG concentrations: At 0.2 mM IPTG, glucose concentration significantly affected the results, particularly at 10 g/L, where yields were extremely low, in stark contrast to the other groups.

4. Significant intra-group variability: At the same IPTG concentration, different glucose levels often exhibited significant differences, particularly at 0.4 mM and 0.8 mM IPTG.

Figure 24. Optimal inducer concentration and glucose concentration at different time points

Figure 24 shows the color distribution after 36 hours of fermentation. A broad warm (orange-red) region forms from the center-left to the center-upper portion of the image (approximately IPTG 0.2–0.6 mM, glucose 20–35 g/L), indicating medium-to-high yields within this band. A localized dark red region appears in the upper right corner (high IPTG ≈0.75–1.0 mM, high glucose ≈35–40 g/L), clearly demarcated from the surrounding area by a series of contour lines, indicating a local peak or maximum. The vertical band at the left edge (IPTG near 0) is generally cooler, indicating generally low yields under no or very low induction conditions. After 48 hours of fermentation, the high-yield zone significantly expanded and shifted upward: a larger, darker red area with higher color intensity formed in the upper right quadrant (IPTG ≈0.6–1.0 mM, glucose ≈30–40 g/L). Compared to 36 hours, this region exhibited increased red intensity and area, indicating the overall highest yield in both figures. The dark blue lowest depression, located at low to medium IPTG and low to medium glucose levels (approximately IPTG ≈0.15–0.30 mM, glucose ≈5–12 g/L), formed a distinctly closed, cool-colored cavity. The color was darker and more concentrated than the low-value portion at 36 hours.

In contrast, the highest color intensity at 48 hours was significantly higher than at 36 hours (the upper limit of the color scale expanded to approximately 125 pg), and the high-yield zone at 48 hours was concentrated in the higher glucose and slightly higher IPTG regions. At 36 hours, a broad warm plateau appeared to the left of the center, with a localized peak in the upper right corner. Both figures show abrupt gradient changes, but the gradient is steeper (with denser contours) in the high-yield region at 48 h, indicating that yield at this time point is more sensitive to changes in IPTG/glucose concentrations at certain boundaries.

Overall, the highest yields in both figures occur in the high glucose (≈30–40 g/L) and medium-high to high IPTG (≈0.6–1.0 mM) regions. The peak intensity and area at 48 h are both greater than those at 36 h. From 36 to 48 h, the high-yield region converges toward higher glucose and IPTG concentrations, with a significant increase in peak yields. Low-yield extremes are more concentrated and have steeper boundaries at 48 h. The peak L-DOPA yield at 48 h is significantly higher than at 36 h, and the high-yield region is concentrated to the upper right in the parameter space of IPTG and glucose.

Finally, we analyzed the inducer concentration, glucose concentration and time together. In the three-dimensional results of Figure 25, we can see that 0.8-1.0mM, 40g/L, 36-48h, the fermentation results are better. Finally, we chose the conditions of 0.8mM, 40g/L, 48h for the fermentation of E. coli ECN.

af171a22dfe2162d17b224bb71f5419a

Figure 25. Effects of different inducer concentrations, glucose concentrations, and time on levodopa

After we have explored the optimal inducer concentration, glucose concentration and time for L-dopa production in E. coli BL21 (DE3), the next step is to transform plasmid 1 and the optimized plasmid 2 into E. coli ECN, because our ultimate goal is to let probiotics produce L-dopa.

As shown in Figure 26, the transformation diagram on the left proves that plasmid 1 and plasmid 2 were successfully transformed into ECN. In addition, in order to further verify that there is no problem with the transformed plasmid, we used colony PCR for verification. The final amplified band length is 800bp, indicating that the transformation is successful. The next step is to select the correct single clone, expand the culture, and then induce fermentation to produce levodopa.

Figure 26. Plasmid 1 and plasmid 2 were transformed into E. coli ECN (left), and the electrophoresis results of colony PCR identification were shown (right).

We then fermented the successfully transformed ECN using the optimal conditions obtained in the BL21(DE3) host strain. After fermentation, we analyzed the fermentation samples using HPLC in triplicate. Figure 27 shows the peaks of the three replicates, revealing the concentrations of 1.064 g/L, 1.065 g/L, and 1.069 g/L, respectively.

Figure 27. Peak diagram of levodopa production after HPLC detection of ECN fermentation

Learn2:

In this round of experiments, we first identified the optimal TyrA source and RBS sequence. Then, through fermentation testing, we ultimately determined the optimal fermentation conditions in ECN: 40 g/L glucose, 0.8 mM IPTG, and a fermentation time of 48 hours. The results revealed the following key insights:

First, the experimental data showed that increasing the fermentation time significantly increased the overall L-DOPA yield. The yield under 48 hours was generally higher than that under 36 hours, confirming the importance of production time in the system and suggesting that future optimization efforts will require attention to the kinetics of product accumulation.Second, the coupling effect of parameters was significant. The optimal glucose concentration varied under different IPTG levels. Under moderate IPTG conditions, moderate glucose concentrations yielded better results, while under high IPTG conditions, high glucose concentrations were required to maintain high yields. This demonstrates that optimizing a single variable is insufficient; there is an interaction between the inducer and the carbon source, and finding a balance is more critical than simply increasing a single condition.Third, a distinct "yield valley" appeared in the experiment, demonstrating the system's sensitivity to parameter changes. If conditions are slightly inappropriate, yield can drop dramatically. This lesson teaches us that stability and reproducibility are crucial for subsequent process design, as otherwise, fluctuations between batches are likely to occur.Fourth, by comparing the contour distributions at 36 and 48 hours, we also realized that plotting a response surface and identifying high-yield "islands" is more intuitive and effective than simply comparing individual data points. This provides guidance for more intensive sampling within the local optimal range and even for implementing response surface design experiments.

Finally, from a future perspective, the greatest value of our learning lies in: first, allowing us to further refine and replicate the current optimal parameters, such as the 40 g/L and 0.8 mM combination; second, providing a foundation for scale-up experiments and fed-batch strategies. After all, high yields under high sugar conditions are likely to be practical in industrial settings.

References
  1. Monzio Compagnoni G, Di Fonzo A, Corti S, et al. The role of mitochondria in neurodegenerative diseases: the lesson from Alzheimer’s disease and Parkinson’s disease[J]. Molecular neurobiology, 2020, 57(7): 2959-2980.
  2. Xie A, Gao J, Xu L, et al. Shared mechanisms of neurodegeneration in Alzheimer’s disease and Parkinson’s disease[J]. BioMed research international, 2014, 2014(1): 648740.
  3. Chopade P, Chopade N, Zhao Z, et al. Alzheimer's and Parkinson's disease therapies in the clinic[J]. Bioengineering & Translational Medicine, 2023, 8(1): e10367.
  4. Ramanan V K, Saykin A J. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders[J]. American journal of neurodegenerative disease, 2013, 2(3): 145.
  5. Khan A U, Akram M, Daniyal M, et al. Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder[J]. International Journal of Neuroscience, 2019, 129(1): 55-93.
  6. Cui L, Hou N N, Wu H M, et al. Prevalence of Alzheimer's disease and Parkinson's disease in China: an updated systematical analysis[J]. Frontiers in aging neuroscience, 2020, 12: 603854.
  7. Manoharan S, Guillemin G J, Abiramasundari R S, et al. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a mini review[J]. Oxidative medicine and cellular longevity, 2016, 2016(1): 8590578.
  8. Fernández-Ruiz J, Romero J, Ramos J A. Endocannabinoids and neurodegenerative disorders: Parkinson’s disease, Huntington’s chorea, Alzheimer’s disease, and others[J]. Handb Exp Pharmacol, 2015, 231: 233-259.